@article{fdi:010081149,
  title = {{P}rogress and new horizons toward a {VAR}2{CSA}-based placental malaria vaccine},
  author = {{D}oritchamou, {J}. {Y}. {A}. and {S}uurbaar, {J}. and {T}uikue {N}dam, {N}icaise},
  editor = {},
  language = {{ENG}},
  abstract = {{I}ntroduction: {S}everal malaria vaccines are under various phases of development with some promising results. {I}n placental malaria ({PM}) a deliberately anti-disease approach is considered as many studies have underlined the key role of {VAR}2{CSA} protein, which therefore represents the leading vaccine candidate. {H}owever, evidence indicates that {VAR}2{CSA} antigenic polymorphism remains an obstacle to overcome. {A}reas covered: {T}his review analyzes the progress made thus far in developing a {VAR}2{CSA}-based vaccine, and addresses the current issues and challenges that must be overcome to develop an effective {PM} vaccine. {E}xpert opinion: {P}hase {I} trials of {PAMVAC} and {PRIMVAC} {VAR}2{CSA} vaccines have shown more or less satisfactory results with regards to safety and immunogenicity. {T}he second generation of {VAR}2{CSA}-based vaccines could benefit from optimization approaches to broaden the activity spectrum against various placenta-binding isolates through continued advances in the structural understanding of the interaction with {CSA}.},
  keywords = {{M}alaria ; pregnancy ; plasmodium falciparum ; vaccine ; var2csa},
  booktitle = {},
  journal = {{E}xpert {R}eview of {V}accines},
  volume = {[{E}arly access]},
  numero = {},
  pages = {[12 p.]},
  ISSN = {1476-0584},
  year = {2021},
  DOI = {10.1080/14760584.2021.1878029},
  URL = {https://www.documentation.ird.fr/hor/fdi:010081149},
}